32 results about "Allergy medications" patented technology

The present invention comprises an all-natural composition of matter and methods of delivering nutrients, medicines, pain relievers, antioxidants, antidotes, antibiotics and various active ingredients and supplements directly to the affected area of the body. The all-natural carrier composition consists essentially of the combination of a natural oil, water, salt(s), natural emulsifier, natural sugar(s), plant extracts, natural acid(s), starch and natural flavor(s). The active substances that are mixed with the all-natural carrier composition, include, but are not limited to, drugs, vitamins, minerals, antibiotics anti fungal agents, antioxidants, diuretics, allergy medicines, anti-inflammatory agents, muscle relaxers, pain reducers, diabetic drugs, neuropathy drugs, chemotherapy agents, arthritis drugs, lotions for eczema, shingles, psoriasis, skin rash; herbal medicines, erectile dysfunction drugs, hormones, cholesterol drugs, essential fatty acids, and the like. The all-natural carrier composition facilitates the penetration of active substances into the dermal layer of the skin.

The invention discloses Graphostroma sp. 3A00421 and applications of fermentation compounds of the Graphostroma sp. 3A00421, wherein the Graphostroma sp. 3A00421 is preserved in China Center for TypeCulture Collection on October 30, 2017, and has the preservation number of CCTCC NO: M 2017637, and the preservation address is Wuhan University in Wuhan city in China. According to the present invention, the fermentation compounds of the Graphostroma sp. 3A00421 have anti-allergic activity and anti-inflammatory activity, and can be used for preparing anti-allergic or anti-inflammatory drugs; andthe new compound source is provided for the research and development of anti-allergic and anti-inflammatory drugs, the important significance is provided for the development of marine drugs in China,the effective applications of deep-sea microbial resources can be promoted, and good application prospect is provided.

The invention discloses andrasone compounds derived from deep sea fungi, a preparation method thereof, and an application of the compounds in the preparation of anti-allergic drugs. The structures ofthe anrasone compounds 1-14 derived from the deep sea fungi are respectively represented by formulas I-XIV, and the anrasone compounds 1-14 can be used for preparing anti-allergic drugs.

The invention discloses an antibacterial and hypoallergenic adult paper diaper and a preparation method thereof. The diapers are sequentially superimposed with a skin-friendly layer, a liquid instant absorption layer and a leak-proof water-proof layer, which are prepared by hot pressing; the skin-friendly layer is made of natural antibacterial materials chitosan and antibacterial drugs combined with inorganic materials, and adopts electrospinning technology The preparation of non-woven fabrics has a high specific surface area and good absorption. The release of antibacterial drugs loaded in inorganic materials can effectively inhibit bacteria and reduce bacterial growth; the absorbent fiber non-woven fabric is used in the liquid instant absorption layer, and at the same time Adding water-absorbing polymers and nano-activated carbon particles to form multiple barriers, not only has the function of air permeability and high water absorption, but also has the characteristics of natural antibacterial and deodorizing. When the ambient temperature is high, moisture and heat are easy to pass through. It is not easy to produce heat and diaper rash; at the same time, the addition of antibacterial and anti-allergic drugs can reduce the growth of bacteria, do not irritate the user's skin, and improve comfort and safety.

The invention provides a quinazolinone-containing diaryl urea compound and a preparation method and application thereof. The quinazolinone-containing diaryl urea compound can obviously inhibit LAD2 cells from releasing beta-hexosaminidase, shows obvious dosage association, can be used for preparing an antiallergic medicament, and particularly can be used for preparing a medicament for antagonizingLAD2 cells from releasing beta-hexosaminidase so as to reduce pain and a load of a patient. The preparation method provided by the invention is easy in obtaining of raw material sources, mild in reaction condition, simple in operation in the reaction process and cheap in used reagent.

The invention discloses a huperzine A acupoint sustained-release gel patch for treating senile dementia and a preparation method thereof. When in use, the sustained-release gel patch is applied to theDazhui acupoint of the governor meridian of a patient, huperzine A is absorbed by the skin of the Dazhui acupoint and distributively enters the brain tissues to play a role in brain-targeted treatment, and entry of drugs into the blood circulation system is reduced, so that adverse reactions are avoided; and meanwhile, the patch belongs to a novel hydrogel drug delivery system, a preparation matrix is soft, comfortable and high in skin affinity, the patch is safe, non-irritating and non-allergic to the skin, and the drug action time is long, so that the drug delivery frequency is reduced. Therefore, the patch solves the problem of poor curative effect or adverse reactions caused by the fact that AD patients often forget to take medicines or take excessive medicines or take wrong medicinesdue to weakened memory and reduced intelligence, provides a novel medicinal preparation which is reliable in curative effect, convenient to use, safe and non-toxic for the treatment of the AD patients, and has important clinical values and wide market prospects.

The invention discloses a transdermal therapeutic system of huperzine A and derivatives thereof. A patch disclosed by the invention is safe, non-irritating and non-allergic to skin, and long in drug action time, so that the administration frequency is reduced. The medicine can be continuously released for a long time, the peak valley phenomenon of blood concentration caused by oral administration is avoided, the first-pass effect of the liver and degradation of the medicine in the gastrointestinal tract are avoided, the transdermal therapeutic system is suitable for patients who fall asleep, do not react or cannot swallow the oral medicine (the compliance of the patients is improved), and administration can be interrupted at any time when side effects are found.

The invention relates to anti-allergic sulfated polysaccharide and a preparation method and application thereof. The anti-allergic sulfated polysaccharide uses sulfated polysaccharide as a raw material, is obtained by removing divalent metal ions from the raw material and has the characteristics of low molecular weight and high content of sulfuric acid groups, wherein the molecular weight of the anti-allergic sulfated polysaccharide is 600 Da-1000 Da, and the retention degree of the sulfuric acid groups relative to the raw material sulfated polysaccharide is more than or equal to 95% by mass.The method for preparing the anti-allergic sulfated polysaccharide is simple in production process and high in production efficiency, and the obtained anti-allergic sulfated polysaccharide is high inanti-allergic activity and very suitable for developing anti-allergic medicines or functional foods.

The invention discloses the application of coyne in the preparation of anti-allergic drugs, by comparing the degranulation of KU812 cells, the degree of swelling of the toes, the degree of Evans blue exudation of the toes, HE staining of foot skin tissue sections, and the release of serum histamine To evaluate the drug group to be tested, the normal saline control group and the normal control group, to evaluate the therapeutic effect of the drug on allergic diseases, and to determine that coyne can be used in the preparation of anti-allergic drugs. Coin can effectively alleviate the symptoms of local and systemic allergic reactions in mice; reduce mast cell degranulation and significantly improve the symptoms caused by allergic reactions.

The invention discloses an online medical system based on a block chain, which comprises a medical information collection module, a medical matching treatment module and a medical progress module, and the medical matching treatment module further comprises a comprehensive analysis module and a patient query module, the comprehensive analysis module is used for a doctor to analyze the diagnosis condition and the treatment condition of an illness state similar to the illness state of a patient in a database by using big data, so that the doctor can propose a better treatment scheme, and the patient query module is used for the doctor to query and analyze allergic drugs and previous cases of the patient, and the medical progress module further comprises a medicine transportation module, a patient feedback module and a patient evaluation module. The system analyzes and records the illness state information of a patient through the medical information collection module by using the block chain technology, recommends a suitable doctor for the patient for treatment through the medical matching treatment module, and carries out the full-stage follow-up of the medical condition of the patient through the medical progress module.

The invention belongs to the field of automatic identification technologies applied in clinic identification of patients with allergic history. The clinic medical record allergic history prompting device comprises a module with an identifiable marker, and a writing pad module for detecting and identifying an identifiable marker and providing information prompt. The identifiable marker module is fixed on a clinic medical record. The writing pad module is located in a writing pad. If the marker is a thin magnetic plate, a hardware circuit used for detecting a magnetic substance is arranged in the writing pad module. If the identifiable marker is an electronic tag with a radio frequency chip and an antenna coil, a reader circuit used for detecting the electronic tag is arranged in the writing pad module. The identifiable marker can be made in a label-like structure with a sticker on one side. An information prompting method provided by the invention is at least one or combination of sound, light emission and liquid crystal display. The name of a specific allergy drug and the general information of a patient can be written in the radio frequency identification chip of the electronic tag.

The invention discloses an application of 4-methylumbelliferone in preparation of antiallergic drugs, the chemical structural formula of the 4-methylumbelliferone is shown in the specification, in an in-vitro experiment, through an in-vitro research method for comparing RBL-2H3 and BMMCs degranulation and an in-vivo experiment research method for a passive sensitization model PCA and an active systemic sensitization model ASA, the application of 4-methylumbelliferone in preparation of antiallergic drugs is realized, and the application of 4-methylumbelliferone in preparation of antiallergic drugs is realized. It is determined that the 4-methylumbelliferone can relieve the degranulation effect of IgE-mediated mast cells and effectively relieve local and systemic anaphylactic reaction symptoms of an organism.

The invention discloses the application of vitamin K3 in the preparation of anti-allergic drugs. Vitamin K3 has a clear therapeutic effect on improving anaphylactoid symptoms. By comparing the degranulation of KU812 cells, the degree of swelling of the toe, and the degree of Evans blue exudation of the toe , Serum histamine release evaluation test drug group, normal saline control group and normal control group, to evaluate the therapeutic effect of drugs on allergic diseases, to determine that vitamin K3 can be used in the preparation of anti-allergic drugs. Vitamin K3 can effectively alleviate the symptoms of local and systemic anaphylaxis in mice; reduce mast cell degranulation and significantly improve the symptoms caused by anaphylaxis.

The invention discloses an application of licochalcone A in preparation of an anti-anaphylactoid drug. KU812 cell degranulation, toe swelling degree, toe Evans blue exudation degree and serum TNF-alpha release amount are compared to evaluate a to-be-detected medicine group, a normal saline control group and a normal control group, so that the treatment effect of the medicine on anaphylactoid diseases is evaluated, and the invention determines that the licochalcone A can be used for preparing the anti-anaphylactoid drug. The licochalcone A can effectively relieve local and systemic anaphylactoid reaction symptoms of mice; and the licochalcone A can reduce mast cell degranulation, and remarkably improve symptoms caused by anaphylactoid.

The invention discloses application of Licochalcone A in preparation of an antiallergic drug. A to-be-detected drug group, a normal saline control group and a normal control group are evaluated by comparing a mastocyte degranulation degree, a mouse toe swelling degree, a toe Evans blue exudation degree and a body temperature lowering degree, so that the treatment effect of the drug for allergic diseases is evaluated; a result determines that the Licochalcone A can be used for preparing the antiallergic drug. The Licochalcone A can effectively relieve local and systemic anaphylactic reaction symptoms of mice. Mastocyte degranulation is reduced, and symptoms caused by allergy are remarkably eliminated.

The invention discloses halogenated diarylurea compounds and application thereof in preparation of an antiallergic drug, and discloses for the first time that the halogenated diarylurea compounds caneffectively antagonize beta-aminohexylglycosidase release and histamine release of human basophilic granulocyte KU812 caused by C48 / 80, so as to inhibit anaphylactoid reaction. Therefore, when the halogenated diarylurea compounds are used as an anti-allergic preparation, the types of anti-allergic medicines are enriched, and more possible treatment schemes are provided for clinical anti-allergic treatment.

The invention discloses application of chrysin in preparation of anaphylactoid-resistance drugs. Degranulation of KU812 cells, swelling degree of toes, Evens blue exudation degree of toes, HE stainingof foot skin tissue slices and burst size of serum histamine are compared, so that a to-be-tested drug group, a normal saline control group and a normal control group are evaluated, the therapeutic effect of the drugs on anaphylactoid diseases is evaluated, and it is determined that chrysin can be applied to preparation of the anaphylactoid-resistance drugs. Through chrysin, local and systemic anaphylactoid-reaction symptoms of mice can be alleviated effectively, degranulation of mast cells can be reduced, and a significant improvement effect is performed on anaphylactoid symptoms.

The invention discloses antiallergic drug coating composition. The antiallergic drug coating composition is characterized by comprising antiallergic drug particles and polymer A particles, wherein the polymer A is selected from sodium alginate or chitosan, and the antiallergic drug particles account for 15%-20% of the total mass. The drug composition is applied to the inside of the paranasal sinus (by spraying or brushing) to form a drug coating, drug ingredients in the coating are released slowly, and long-term fixed-point and quantitative administration to the part of lesion can be realized. The invention further provides a preparation method and an application of the composition.

The invention provides a quinazolinone-containing diaryl urea compound and a preparation method and application thereof. The quinazolinone-containing diaryl urea compound can obviously inhibit LAD2 cells from releasing beta-hexosaminidase, shows obvious dosage association, can be used for preparing an antiallergic medicament, and particularly can be used for preparing a medicament for antagonizingLAD2 cells from releasing beta-hexosaminidase so as to reduce pain and a load of a patient. The preparation method provided by the invention is easy in obtaining of raw material sources, mild in reaction condition, simple in operation in the reaction process and cheap in used reagent.

The invention discloses the application of the deep-sea fungus Graphstroma sp. 3A00421 and its fermentation compound. The deep-sea fungus Graphstroma sp.3A00421 of the present invention is preserved in the China Center for Type Culture Collection, the preservation number is CCTCC NO: M 2017637, the preservation address is Wuhan University, China, and the preservation date is October 30, 2017. The fermented compound of the deep-sea fungus Graphstroma sp.3A00421 of the invention has anti-allergic and anti-inflammatory activities, and can be used to prepare anti-allergic drugs or anti-inflammatory drugs. The invention not only provides a new compound source for the research and development of anti-allergic and anti-inflammatory drugs, is of great significance to the development of marine drugs in my country, but also promotes the effective application of deep-sea microbial resources and has a good application prospect.

The invention discloses the application of the fermented compound of Aspergillus terreus H768 in the preparation of antiallergic medicine. Aspergillus terreus fermentation compound of the present invention is obtained by fermentation and extraction of Aspergillus terreus H768, and its structural formula is as shown in formula (I): Aspergillus terreus H768 (Aspergillus terreus H768), preserved in China Type Culture Collection Center, preservation number It is CCTCC NO: M 2017121, and the deposit address is China. Wuhan. Wuhan University, and the deposit date is March 15, 2017; the invention finds that the Aspergillus fermented compound has strong anti-allergic activity and can be used to prepare anti-allergic drugs. The invention provides a new source of compounds for the research and development of anti-allergic drugs, which is of great significance to the development of marine drugs in my country, and can also promote the effective application of deep-sea biological resources, and has a good application prospect.

The invention relates to the technical field of medical evaluation and detection, and in particular relates to a method for detecting induced anaphylactoid reaction of intravenous injection medicines. The method comprises the following steps: observing anaphylactoid reaction symptoms of experimental animals after being dosed in a certain time by supplying different doses of tested medicines to intravenous injection of the experimental animals, and judging the grade of anaphylactoid reaction strength of intravenous injection administration of the tested medicines according to scale scores of the anaphylactoid reaction symptoms. According to the method disclosed by the invention, by adopting the anaphylactoid reaction symptoms of the animals after being dosed as 'gold standards', the whole process of dynamic reaction of the occurrence of clinical systemic anaphylactoid reaction can be relatively well simulated, so that the method can be applied to the detection and determination of anaphylactoid reaction of the intravenous injection medicines, also can be applied to the screening of anti-anaphylactoid medicines and the research of systemic anaphylactoid pathogenesis and medicine action mechanism, and has the advantages of simplicity and convenience in operation, short experimental period, good detection reproducibility, clinically-close results and the like.

The invention discloses a pharmaceutical composition and an application thereof in treating rhinitis, and relates to the technical field of rhinitis treatment. Through combined administration of vitamin C and antiallergic medicines, immunity of a human body and strain capacity to abnormal changes are improved, so that symptoms of rhinitis and allergic recurrence become more and more slight, and the effect of treating rhinitis is gradually achieved.